Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Medicenna Therapeutics Corp T.MDNA

Alternate Symbol(s):  MDNAF

Healthcare Biotechnology
Medicenna Therapeutics Corp. is a Canada-based clinical-stage immunotherapy company. The Company is focused on the development of selective versions of interleukin-2 (IL-2), interleukin-4 (IL-4) and interleukin-13 (IL-13) Superkines and Empowered Superkines for the treatment of cancer, inflammation and immune-mediated diseases. Its long-acting IL-2 Superkine, MDNA11, is an IL-2 with superior... see more

Recent & Breaking News (TSX:MDNA)

Medicenna Announces March 31, 2020 Year-End Results

Canada NewsWire May 15, 2020

Medicenna Announces Upcoming Presentations at the ASCO Annual Meeting

PR Newswire May 4, 2020

Medicenna Announces Full Exercise of Over-Allotment Option as Part of $40.25 Million Public Offering

Canada NewsWire April 15, 2020

Medicenna's IL-2 Superkine, MDNA19, Demonstrates Best-in-Class Features in a Non-Human Primate Study

PR Newswire March 25, 2020

Medicenna Announces Closing of Public Offering of $35 Million

Canada NewsWire March 17, 2020

Medicenna Announces Intention to File Final Short Form Prospectus

Canada NewsWire March 12, 2020

IIROC Trade Resumption - MDNA

Canada NewsWire March 4, 2020

Medicenna Announces Pricing of $35 Million Overnight Marketed Offering of Common Shares

Canada NewsWire March 4, 2020

IIROC Trading Halt - MDNA

Canada NewsWire March 3, 2020

Medicenna Announces Overnight Marketed Offering of Common Shares

Canada NewsWire March 3, 2020

Medicenna Reports Third Quarter Fiscal 2020 Financial Results

Canada NewsWire February 13, 2020

President and CEO of Medicenna Therapeutics Corp., Dr. Fahar Merchant, is Featured on The Stock Day Podcast

Newsfile January 21, 2020

Medicenna Reports Compelling Results from Recurrent Glioblastoma Trial When Compared to an Eligibility-Matched Control Arm

PR Newswire January 13, 2020

Medicenna Receives $1.3 Million Through Early Warrant Exercises

Canada NewsWire January 8, 2020

Medicenna Presents Additional Encouraging Phase 2b Clinical Data at the Inaugural Glioblastoma Drug Development Annual Summit

PR Newswire December 12, 2019

Medicenna Announces Presentation of the MDNA55 Clinical Trial at the Inaugural Glioblastoma Drug Development Annual Summit

Canada NewsWire December 9, 2019

Medicenna Reports Promising Efficacy in Phase 2b MDNA55 Clinical Trial at the Society for Neuro-Oncology Annual Meeting

Canada NewsWire November 25, 2019

Medicenna Reports Improved Drug Distribution of MDNA55 with Novel Delivery Technology in Phase 2b Recurrent Glioblastoma Clinical Trial

PR Newswire November 21, 2019

Medicenna To Host Key Opinion Leader Call Focused on Latest MDNA55 Recurrent Glioblastoma Phase 2b Clinical Study Results

Canada NewsWire November 20, 2019

Medicenna to Host a Key Opinion Leader Symposium on MDNA55 for Treatment of Recurrent Glioblastoma

PR Newswire November 18, 2019